Archive for 2006

  • 松下修三. シンポジウム3「より良いHAARTに向けて」-耐性検査の意義とタイミング.  第20回日本エイズ学会学術集会・総会. 2006.11.30-12.2. 東京.

  • 吉村和久、柴田潤二、小糸 厚、松下修三. In vitroにおける抗HIV-1中和単クローン抗体とその他の薬剤との相互作用の研究. 第20回日本エイズ学会学術集会・総会. 2006.11.30-12.2. 東京.

  • 柴田潤二、吉村和久、小糸厚、松下修三. 抗HIV-1 gp120-V3抗体より逃避したV2領域変異ウイルスの中和抵抗性メカニズムの解析. 第54回日本ウイルス学会総会. 2006.11.18-21. 名古屋

  • 池田輝政、柴田潤二、吉村和久、小糸 厚、松下修三. 長期間HAART有効症例における残存HIVと組込み部位の関連性. 第54回日本ウイルス学会総会. 2006.11.18-21. 名古屋

  • Yoshimura K, Shibata J, Honda A, Koito A, Matsushita S. A novel potent neutralizing anti-V3 monoclonal antibody, KD-247, that shows faborable synergism with anti-CCR5 inhibitors in vitro. 7th AIDS Seminar in Kumamoto, Sep 21-22, 2006.

  • Shibata J, Yoshimura K, Honda A, Koito A, Murakami T, Matsushita S. Impact of V2 mutations for escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary HIV-1 isolate. 7th AIDS Seminar in Kumamoto, Sep 21-22, 2006

  • Ikeda T, Shibata J, Yoshimura K, Koito A, Matsushita S. Recurrent HIV-1 integration at BACH2 locus in resting CD4+ T cell populations during effective HAART. 7th AIDS Seminar in Kumamoto, Sep 21-22, 2006.

  • Matsushita S., Shibata J., Honda A., Murakami T, Eda Y, Koito A, Yoshimura . Development of broadly immunotherapy. AIDS Vaccine 2006 Conference, Amsterdam, the Netherlands, Aug. 29-Sep.1, 2006.

  • Eda Y, Takizawa M, Murakami T., Maeda H., Kimachi K., YonemuraH, Koyanagi S, Shiosaki K, Higuchi H, Makizumi K, Nakashima T ,Osatomi K., Tokiyoshi S, Matsushita S, Yamamoto N. Honda M. Sequential immunization with V3 peptides from primary HIV-1 produces cross-neutralizing antibodies against primary isolates with matching narrow neutralization sequence motif.J. Virol. 80:5552-5562,2006.

  • Eda Y, Murakami T, Ami Y, Nakasone T, Takizawa M, Someya K, Kaizu M, Izumi Y., Yoshino, N., Matsusita, S.,Higuchi, H., Matsui, H., Shinohara, K., Takeuchi, H., Koyanagi, S., Yamamoto, N. and Honda M. Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affordssterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection. J. Virol. 80:5563-5570, 2006

  • Davis DA, Brown CA, Singer KE., Wang V, Kaufman J, Stahl SJ, Wingfield P, Maeda K, Harada S, Yoshimura K, Kosalaraksa, P, Mitsuya H, Yarchoan R Antiviral Res. 72:89-99, 2006

  • Yoshimura K, Shibata J, Kimura T, Honda A, Maeda Y, Koito A, Murakami T, Mitsuya H, Matsushita S. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favorable synergism with anti-CCR5 inhibitors. AIDS .20:2065-2073, 2006.

  • Yoshimura, K., Shibata, J., Honda A., Murakami,T., Mitsuya,H., Koito, A., and Matsushita S.: Resistance Profile of A Novel Broadly Neutralizing Anti-HIV Monoclonal Antibody, KD-247 That Has Favorable Synergism with Anti-CCR5 Inhibitors In Vitro.13th Conference on Retroviruses and Opportunistic Infections. Denver, USA, Feb.4-9, 2006.

  • Shibata, J., Yoshimura, K., Honda A., Murakami,T., Koito, A., and Matsushita S.: A Role of Mutations in Non-V3 Envelope Regions for Escape from a Broad Neutralizing Anti-V3 Monoclonal Antibody, KD-247, during in vitro Selection. 13th Conference on Retroviruses and Opportunistic Infections. Denver, USA, Feb.4-9, 2006